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Contents l ists avai lable at ScienceDirectEditorialGenetic diagnosis of autosomal dominant polycystic kidney disease:
linkage analysis versus direct mutation analysisAutosomal dominant polycystic kidney disease (ADPKD) is
one of the most common monogenic diseases and accounts
for 2e5% of end-stage renal disease (ESRD) [1]. Mutations in
2 genes mainly cause ADPKD. The polycystic kidney disease 1
(PKD1) locus accounts for approximately 85% of the patients,
and the polycystic kidney disease 2 (PKD2) locus accounts for
approximately 15% of the patients [2]. The typical phenotype
is progressive renal cyst development and enlargement leading
to decreased renal function. ADPKD slowly develops over
several decades, and disease progression to ESRD is highly
variable according to genetic loci. The patients with PKD1 mu-
tation have larger kidneys and earlier onset of ESRD than those
with PKD2 mutation (mean age at ESRD, 53.4 vs. 72.7 years)
[3,4].
The ability and demand for genetic testing are recently
changing for several reasons [1]. First, technological advances
in genome sequencing (targeted next-generation sequencing)
have resulted in the development of automated high-
throughput tests, which are getting cheaper. Second, genetic
mutation is a key determinant of phenotype in ADPKD. Genetic
and allelic effects mainly determine the progression of ADPKD.
Third, the long and expensive treatment with new drugs
to suppress the cyst growth might request for genetic tests.
Genetic diagnosis could guide who will be beneﬁted by
the treatment. Fourth, presymptomatic testing in prenatal or
younger at-risk individuals might be advocated in early treat-
ment or familial planning.
There are 2 methods for genetic testing: DNA linkage anal-
ysis and direct mutation screening. Linkage analysis detects
excessive cosegregation of the putative alleles underlying a
familial phenotype [5]. For many years, linkage analysis
has been the primary tool used for genetic disease with familial
aggregation. However, there are several limitations to linkage
testing. Linkage analysis cannot be used if a family is small. A
minimum of 4 affected family members' DNA in 2 generations
is required. Linkage analysis is possible to determine the
genetic loci, but information of pathogenic mutation cannot
be obtained [6].
Direct mutation analysis is another genetic method used for
ADPKD. It involves direct sequencing of the entire coding
regions of both PKD1 and PKD2, including intron/exon bound-
aries. To date, more than 1,272 PKD1 and 202 PKD2 different
pathologic mutations have been reported (http://pkdb.mayo.
edu). The major limitation of direct mutation analysis is thehttp://dx.doi.org/10.1016/j.krcp.2016.04.004
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).failure to ﬁnd pathogenic mutations in the remaining more
than about 10% of ADPKD families [2]. However, direct muta-
tion analysis has become a useful genetic testing method in
ADPKD. Direct mutation analysis needs only a DNA sample
from the test subject. Direct mutation analysis is possible if
the proband is suspected to have a de novo mutation. In addi-
tion, direct mutation analysis informs the mutation position
and type. Recent studies have reported that allelic effects of
mutation contribute to the ADPKD phenotype. PKD1 truncating
mutations were associated with more severe phenotype than
nontruncating mutations (mean age at ESRD, 55.6 vs. 67.9
years) [7e9].
Entezam et al [10] performed a direct mutation analysis on
an ADPKD family unlinked to both PKD1 and PKD2. Direct
mutation analysis revealed a pathogenic mutation in the
PKD2 gene (c.1094þ1G>C). Misinterpretation of linkage data
was due to crossing over between the PKD2 intragenic and
the nearest downstream marker (D4S2929). Homozygosity of
upstream markers causes the recombination indistinguishable.
This article is informative to clinical nephrologists because a
negative test of linkage analysis cannot be used for ADPKD
exclusion. Even in an unlinked ADPKD pedigree, direct
mutation analysis can identify the causative mutation. In the
future, genetic testing of ADPKD may become increasingly
widespread, and direct mutation analysis is more applicable
than linkage analysis. The genotypeephenotype information
based on registries and networks of ADPKD will enhance the
understanding of progression and treatment of ADPKD.
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